[an error occurred while processing this directive] | [an error occurred while processing this directive]
Results and prognostic factors of CyberKnife for lung metastasis
QU Chen-hui, LIU Ning-bo, ZHUANG Hong-qing, SONG Yong-chun, DONG Yang, GONG Lin-lin, YUAN Zhi-yong
Department of Radiotherapy, Cancer Hospital of Tianjin Medical University;Tianjin Key laboratory of Tumor Research and Control;Tianjin 300060, China Corresponding author:YUAN Zhi-yong, Email:zhiyong0524@163.com
Abstract Objective To investigate the effectiveness and toxicity of CyberKnife in the treatment of lung metastases. Methods Treatment details and outcomes were reviewed for 93 targets of 48 histologically verified patients treated by CyberKnife at the CyberKnife Center of Tianjin between September 2006 and June 2010. The median tumor volume was 6.0(0.2－135.2) cm3, the median biological equivalent dose was 140.8(53－180) cGy (α/β=10),the median fraction was 3(1－7) times and the median isodose line was 81%(71%－91%). Results The rate of follow-up is 96%. 33 cases were followed up for more than 2 years. The effective rate was 90.3%.Two targets of 2 patients locally progressed. The 1-and 2-year local control rates, overall survival (OS) rates and progression-free survival (PFS) rates were 98% and 98%, 83% and 63%,and 64% and 37%, respectively. Univariate analyses showed that age older than 60 versus ≤60 years tended to be predictor for PFS (χ2=3.45,P=0.063);The PFS of patients who had single lesion was better than patients with multiple lesions (χ2=4.49,P=0.034);patients with disease-free interval longer than 18 months had better OS (χ2=6.50,P=0.011).Five patients were reported to experience treatment-related grade 1 radiation pulmonary injury, and one each for subcutaneous fibrosis with pigmentation, grade 2 and grade 3 adverse event. Conclusions For patients with lung metastatic lesion, CyberKnife is an effective option with high local control rate and little acute reaction. The long-term outcome and toxicity need further study.
QU Chen-hui,LIU Ning-bo,ZHUANG Hong-qing et al. Results and prognostic factors of CyberKnife for lung metastasis[J]. Chinese Journal of Radiation Oncology, 2012, 21(3): 214-216.
QU Chen-hui,LIU Ning-bo,ZHUANG Hong-qing et al. Results and prognostic factors of CyberKnife for lung metastasis[J]. Chinese Journal of Radiation Oncology, 2012, 21(3): 214-216.
[1] Etienne-Mastroianni B, Freyer G, Cordier JF. Secondary lung cancers. Rev Prat,2003,53:756-759. [2] Brown WT, Wu X, Fayad F, et al. CyberKnife radiosurgery for stage Ⅰ lung cancer:results at 36 months. Clin Lung Cancer,2007,8:488-492. [3] Baumann P, Nyman J, Hoyer M, et al. Outcome in a Prospective Phase Ⅱ trial of medically inoperable stage Ⅰ non-small cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol,2009,27:3290-3296. [4] 吴瑞花,宋勇春,袁智勇,等.肺肿瘤运动规律及其影响因素的研究.中华放射肿瘤学杂志,2011,20:193-196. [5] Kilby W, Dooley JR, Kuduvalli G, et al. The CyberKnife robotic radiosurgery system in 2010.Technol Cancer Res Treat,2010,9:433-452. [6] 王纹,徐国镇,谷铣之,等.全肺照射在鼻咽癌肺转移治疗中的价值.中华放射肿瘤学杂志,1995,4:161-163. [7] Rusthoven KE, Kavanagh BD, Burri SH, et al. Multi-institutional phase Ⅰ/Ⅱ trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol,2009,27:1579-1584. [8] Greco C, Zelefsky MJ, Lovelock M, et al. Preditors of local control after single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases. Int J Radiat Oncol Biol Phys,2011,79:1151-1157. [9] Chen F, Fujinaga T, Sato K, et al. Clinical features of surgical resection for metastasis from breast cancer. Eur J Surg Oncol,2009,35:393-397. [10] Nakagawa T, Kamiyama T, Nakanishi K, et al. Pulmonary resection of metastases from hepatocellular carcinoma:factors influencing prognosis. J Thorac Cardiovasc Surg,2006,131:1248-1254.
2012, Vol. 21 
